patent_istock-643607264_warchi-
warchi / iStockphoto.com
14 June 2018PharmaEllen Sherin

Investing in patent search: tips for practitioners

What is the cost of a single missed reference in the IP world? It depends on the situation. Research programmes that spend millions to develop inventions which turn out to be unpatentable because of prior art, long drawn-out prosecutions with multiple rejections, post-grant invalidities and infringement litigation are just some of the possibilities. No search is perfect, and there is always the chance of missing something—but the better the search, the better the subsequent decision-making.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
27 August 2026   Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.
Pharma
21 August 2026   Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.
Pharma
20 August 2026   A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.